GlassScriptPhysician profile
Mahran Shoukier
NPI 1659633154
$78,038.55
in general payments reported to CMS, 2019-2025
47 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2021: $106 · 2022: $708 · 2023: $4,514 · 2024: $72K · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,865 · Food and Beverage: $5,323 · Travel and Lodging: $2,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,107.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,865.00 |
| Food and Beverage | $5,322.71 |
| Travel and Lodging | $2,826.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $42,037.63 | 2024-2025 | Xt Cdx |
| Emd Serono, INC. | $12,028.67 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $8,953.43 | 2023-2024 | Tazverik, Onivyde |
| Janssen Biotech, INC. | $7,313.04 | 2023-2025 | Rybrevant, Darzalex, Carvykti |
| Pfizer INC. | $1,859.16 | 2024 | |
| Genmab U.S., INC. | $1,392.65 | 2024 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $783.88 | 2022-2025 | Calquence, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $344.68 | 2019-2025 | Opdivo, Opdualag |
| Abbvie INC. | $344.24 | 2023-2024 | Epkinly |
| Novartis Pharmaceuticals Corporation | $254.49 | 2023-2025 | |
| Gilead Sciences, INC. | $245.86 | 2024 | Trodelvy |
| Novocure INC. | $140.22 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $138.28 | 2023 | Imbruvica |
| Incyte Corporation | $133.72 | 2024 | Pemazyre, Monjuvi |
| Lilly USA, LLC | $133.57 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $125.97 | 2021-2023 | Lumakras, Vectibix, Nplate |
| Genzyme Corporation | $125.41 | 2023-2024 | |
| Seagen INC. | $125.00 | 2022 | |
| Karyopharm Therapeutics INC. | $119.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $119.32 | 2023-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $115.08 | 2022-2024 | Xtandi |
| Celgene Corporation | $102.65 | 2023-2024 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $98.98 | 2024 | Iclusig, Ninlaro |
| Daiichi Sankyo INC. | $96.27 | 2024-2025 | Enhertu |
| Tersera Therapeutics LLC | $85.94 | 2024-2025 | Xermelo, Zoladex |
| Deciphera Pharmaceuticals INC. | $74.15 | 2023-2024 | Qinlock, Tgct |
| Taiho Oncology, INC. | $64.19 | 2023-2024 | |
| Glaxosmithkline, LLC. | $63.73 | 2023-2024 | Ojjaara |
| Eisai INC. | $63.29 | 2024-2025 | |
| Blueprint Medicines Corporation | $57.60 | 2024 | Ayvakit |
| Stemline Therapeutics INC. | $49.62 | 2023-2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $46.28 | 2025 | Talvey, Darzalex, Tecvayli |
| Pharmaessentia USA Corporation | $45.97 | 2024 | Besremi |
| Sirtex Medical INC | $40.91 | 2024 | Sir-Spheres Microspheres |
| Jazz Pharmaceuticals INC. | $39.22 | 2023 | |
| Pharmacosmos Therapeutics INC. | $39.03 | 2024 | Monoferric |
| Aveo Pharmaceuticals, INC. | $36.68 | 2023 | Fotivda |
| Boston Scientific Corporation | $35.15 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Kite Pharma, INC. | $29.93 | 2025 | Yescarta |
| Acrotech Biopharma INC. | $23.08 | 2024 | Beleodaq |
| Adaptive Biotechnologies Corporation | $22.02 | 2023 | Clonoseq |
| Recordati_rare_diseases_inc. | $19.79 | 2025 | Sylvant |
| Bayer Healthcare Pharmaceuticals INC. | $19.29 | 2025 | |
| Puma Biotechnology, INC. | $19.08 | 2025 | |
| Mirati Therapeutics, INC. | $18.24 | 2023 | Krazati |
| Apellis Pharmaceuticals, INC. | $13.17 | 2023 | Empaveli |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahran Shoukier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.